Koers Tikun Olam-Cannbit Pharmaceuticals Ltd TEL AVIV STOCK EXCHANGE
Aandelen
TKUN
IL0010843675
Farmaceutische producten
Omzet 2022 | 49,3 186,23 46,05 | Omzet 2023 | 44,23 167,08 41,32 | Marktkapitalisatie | 25,49 mln. 96,29 mln. 23,81 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -48 mln. -181 mln. -44,84 mln. | Nettowinst (verlies) 2023 | -88 mln. -332 mln. -82,21 mln. | EV/omzet 2022 | 1.234.605 x |
Nettoschuld 2022 | 17,5 mln. 66,12 mln. 16,35 mln. | Nettoschuld 2023 | 13,42 mln. 50,69 mln. 12,54 mln. | EV/omzet 2023 | 879.698 x |
K/w-verhouding 2022 |
-0,97
x | K/w-verhouding 2023 |
-0,22
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 61,97% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ifat Kariv
CEO | Chief Executive Officer | 50 | - |
Daniel Spira
AUD | Comptroller/Controller/Auditor | 69 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Revital Aviram
BRD | Director/Board Member | 66 | 15-02-15 |
Erez Navon
BRD | Director/Board Member | 50 | - |
Ifat Kariv
CEO | Chief Executive Officer | 50 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+24,50% | 3,65 mld. | |
+116,79% | 2,02 mld. | |
+80,95% | 59,67 mln. | |
+234,45% | 50,07 mln. |